Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
CA 2402586 A1 · Owner: Stryker Corporation · Inventors: Ripamonti, Ugo; Ramoshebi, Lentsha Nathaniel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition this invention also , features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method the morphogenic protein , is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively the two , components are administered separately in any order.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 23, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 23, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 23, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.